by Tyler Vaglivelo
This is a podcast about advancements in clinical trials as they emerge, before regulatory milestones or publication of associated data. The views expressed are my own, and I have no financial affiliations with the companies discussed, nor is this affiliated with any employer.
Language
🇺🇲
Publishing Since
8/10/2025
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
April 14, 2026
<p>If you have any questions, please reach out at inthepipelinepodcast@gmail.com or on Twitter/X @tdonatellov. Thank you for listening!</p><p><u>Sources:</u></p><p><a href="https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit" target="_blank" rel="noopener noreferer">Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer</a></p><p><a href="https://ir.ideayabio.com/2026-04-13-IDEAYA-Biosciences-and-Servier-Announce-Positive-Topline-Results-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A-02-01-Negative-Metastatic-Uveal-Melanoma" target="_blank" rel="noopener noreferer">IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma</a></p><p><a href="https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-reports-interim-futility-analysis-pivotal" target="_blank" rel="noopener noreferer">Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL</a></p><p><a href="https://us.gsk.com/en-us/media/press-releases/gsk-presents-positive-data-for-b7-h4-targeted-adc-in-gynecological-cancers/" target="_blank" rel="noopener noreferer">GSK presents positive data for B7-H4-targeted ADC in gynecological cancers</a></p><p><u>Corrections</u>:</p><p>Stated that there are >300 primary uveal melanona cases annually in the U.S., this figure is actually >3000 cases. </p><p>Did not mention that the OptimUM-02 trial of darovasertib + crizotinib included 437 patients randomized 2:1 to darovasertib + crizotinib or investigator's choice</p>
March 24, 2026
<p>If you have any questions, please reach out at inthepipelinepodcast@gmail.com or on Twitter/X @tdonatellov. Thank you for listening!</p><p>Topics:</p><p><a href="https://ir.cytomx.com/news-releases/news-release-details/cytomxs-varsetatug-masetecan-epcam-probodyr-adc-continues" target="_blank" rel="noopener noreferer">CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer</a></p><p><a href="https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Announces-Positive-Phase-3-Results-from-the-SUCCESSOR-2-Study-of-Oral-Mezigdomide-in-Relapsed-or-Refractory-Multiple-Myeloma/default.aspx" target="_blank" rel="noopener noreferer">Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma</a></p><p><a href="https://www.relmada.com/for-investors/news/detail/332/relmada-therapeutics-reports-12-month-phase-2-inte" target="_blank" rel="noopener noreferer">Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer</a></p><p><a href="https://www.gene.com/media/press-releases/15106/2026-03-08/genentech-provides-update-on-phase-iii-p" target="_blank" rel="noopener noreferer">Genentech Provides Update on Phase III persevErA Study in ER-Positive Advanced Breast Cancer</a></p><p><a href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-topline-phase-2-results-next" target="_blank" rel="noopener noreferer">Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer</a></p>
January 6, 2026
<p>If you have any questions, please reach out at inthepipelinepodcast@gmail.com or on Twitter/X @tdonatellov. Thank you for listening!</p><p>Topics:</p><p><a href="https://assets.roche.com/f/176343/x/55a0097f19/final_20251211_sabcs-roche-s-virtual-oncology-investor-event.pdf" target="_blank" rel="noopener noreferer">Ph III (lidERA) giredestrant in adjuvant ER+/HER2-negative, early BC</a></p><p><a href="https://ir.ternspharma.com/static-files/a03e11d3-7967-4087-b273-0a871873d43d" target="_blank" rel="noopener noreferer">TERN-701 CARDINAL Trial December 2025 Data Update</a></p><p><a href="https://s201.q4cdn.com/681340001/files/doc_presentations/2025/Dec/01/JANUX-NC-JANX007-PU-DECK-FINAL-12012025.pdf" target="_blank" rel="noopener noreferer">JANX007 Phase 1 Clinical Update</a></p><p><br></p>
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
This is a podcast about advancements in clinical trials as they emerge, before regulatory milestones or publication of associated data.
The views expressed are my own, and I have no financial affiliations with the companies discussed, nor is this affiliated with any employer.
This podcast updates daily.
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
No, this podcast does not typically feature guests.
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.